ORKA Oruka Therapeutics Inc.
Price (delayed)
$9.42
Market cap
$352.69M
P/E Ratio
N/A
Dividend/share
$19.36
EPS
-$3.87
Enterprise value
$292.08M
Highlights
Oruka Therapeutics's EPS has increased by 38% from the previous quarter and by 13% YoY
The company's equity rose by 12% QoQ
The company's quick ratio has shrunk by 51% YoY but it rose by 26% QoQ
Oruka Therapeutics's net income has shrunk by 143% QoQ
Key stats
What are the main financial stats of ORKA
Market
Valuations
Earnings
Shares outstanding
37.44M
Market cap
$352.69M
Enterprise value
$292.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.86
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$88.12M
Net income
-$83.72M
EBIT
-$82.26M
EBITDA
-$82.1M
Free cash flow
-$58.03M
Per share
Balance sheet
Liquidity
EPS
-$3.87
EPS diluted
-$3.87
Free cash flow per share
-$3.46
Book value per share
$10.92
Revenue per share
$0
TBVPS
$23.59
Total assets
$396.02M
Total liabilities
$13.8M
Debt
$968,000
Equity
$382.22M
Working capital
$363.83M
Debt to equity
0
Current ratio
28.89
Quick ratio
28.8
Net debt/EBITDA
0.74
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-38.6%
Return on equity
-39.9%
Return on invested capital
-51%
Return on capital employed
-21.5%
Return on sales
N/A
Dividend yield
205.49%
DPS
$19.36
Payout ratio
N/A
ORKA stock price
How has the Oruka Therapeutics stock price performed over time
Intraday
-1.46%
1 week
-17.3%
1 month
-7.19%
1 year
-54.09%
YTD
-51.42%
QTD
-8.19%
Financial performance
How have Oruka Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$88.12M
Net income
-$83.72M
Gross margin
N/A
Net margin
N/A
Oruka Therapeutics's net income has shrunk by 143% QoQ
ORKA's operating income has dropped by 140% since the previous quarter
Growth
What is Oruka Therapeutics's growth rate over time
Valuation
What is Oruka Therapeutics stock price valuation
P/E
N/A
P/B
0.86
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Oruka Therapeutics's EPS has increased by 38% from the previous quarter and by 13% YoY
ORKA's price to book (P/B) is 100% lower than its last 4 quarters average of 5765.1 and 100% lower than its 5-year quarterly average of 1214.3
The company's equity rose by 12% QoQ
Efficiency
How efficient is Oruka Therapeutics business performance
Oruka Therapeutics's return on assets has shrunk by 190% YoY and by 154% QoQ
The return on equity has dropped by 189% year-on-year and by 120% since the previous quarter
Dividends
What is ORKA's dividend history
DPS
$19.36
Dividend yield
205.49%
Payout ratio
N/A
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Oruka Therapeutics financials performed over time
The company's current ratio has shrunk by 51% YoY but it rose by 26% QoQ
The company's quick ratio has shrunk by 51% YoY but it rose by 26% QoQ
The company's debt is 100% lower than its equity
The company's debt to equity has shrunk by 100% YoY
The company's equity rose by 12% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.